SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Exelixis, Inc. Regains Full Rights to Develop and Commercialize XL184; Bristol-Myers Squibb Company will Make $17 Million Payment in Connection with Return of Drug